Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical biotechnology company that uses AI technology to develop precision antibodies. The company has a strong body of preclinical results and is on pace to file an IND/CTA by year-end 2026 for IBIO-610, its second clinical asset. It also faces significant competition in the industry and may need to raise additional funds for its research and development programs.

Bears say

iBio is a development stage company that relies heavily on intellectual property to protect its potential products, however, its patents and patent applications may not provide sufficient protection from competitors. The company also faces significant competition from larger, more established biotechnology and pharmaceutical companies, and will likely need to raise significant funds in the future to continue its operations. With no current revenue generating products, there are significant financial risks associated with investing in iBio.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.